Panel advising the US regulator rejects MDMA as a treatment for post-traumatic stress disorder
Stay informed with free updates Simply log in to the Pharmaceutical sector myFT Digest – delivered straight to your inbox. A panel of experts convened by the US Food and Drug Administration has voted decisively against the use of MDMA, better known as party drug ecstasy, as a treatment for post-traumatic stress disorder. Tuesday’s ruling … Read more